Spearhead Capital Advisors, LLC Crispr Therapeutics Ag Transaction History

Spearhead Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 25, 2022	SELL	$70.09 - $111.29 $156,020 - $247,731	-2,226 Closed	0 $0
Q3 2021 Oct 27, 2021	SELL	$110.2 - $156.64 $9,256 - $13,157	-84 Reduced 3.64%	2,226 $249,000
Q2 2021 Aug 10, 2021	SELL	$100.84 - $161.89 $140,772 - $225,998	-1,396 Reduced 37.67%	2,310 $374,000
Q1 2021 Apr 28, 2021	BUY	$110.72 - $210.04 $18,822 - $35,706	170 Added 4.81%	3,706 $452,000
Q4 2020 Feb 02, 2021	SELL	$79.67 - $173.23 $47,881 - $104,111	-601 Reduced 14.53%	3,536 $541,000
Q3 2020 Oct 16, 2020	SELL	$78.5 - $100.64 $471 - $603	-6 Reduced 0.14%	4,137 $346,000
Q2 2020 Jul 16, 2020	BUY	$38.5 - $76.05 $159,505 - $315,075	4,143 New	4,143 $304,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.